On Invalid Date, Curis (NASDAQ: CRIS) reported Q2 2023 earnings per share (EPS) of -$0.12, up 29.41% year over year. Total Curis earnings for the quarter were -$11.96 million. In the same quarter last year, Curis's earnings per share (EPS) was -$0.17.
On Invalid Date, Curis (NASDAQ: CRIS) reported Q2 2023 revenue of $2.20 million up 8.19% year over year. In the same quarter last year, Curis's revenue was $2.39 million.
What was CRIS's revenue growth in the past year?
As of Q3 2023, Curis's revenue has grown -3.93% year over year. This is 105.1 percentage points lower than the US Biotechnology industry revenue growth rate of 101.17%. Curis's revenue in the past year totalled $10.21 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.